sur The Rainwater Charitable Foundation
The Rainwater Charitable Foundation Supports Neurodegenerative Drug Research
The Rainwater Charitable Foundation has announced grants totaling over $1 million for three research projects targeting tau protein in neurodegenerative diseases. This funding, part of the Sprint to Lead program, aims to advance preclinical drug candidates by focusing on tau-driven conditions such as progressive supranuclear palsy and other tauopathies.
Dr. Timothy Miller, Dr. Neil Vasdev, and Dr. Markus Zweckstetter have received $350,000 each to support their innovative projects. Dr. Miller is working with antisense oligonucleotides to balance tau isoforms, while Dr. Vasdev's team is developing tau degraders to eliminate harmful tau. Dr. Zweckstetter focuses on small molecules to prevent pathological tau aggregation.
These efforts are part of a larger initiative to translate scientific discoveries into therapies that could offer new hope for patients suffering from these debilitating disorders.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de The Rainwater Charitable Foundation